Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of hematopoietic stem cell and its preparation method and application

A technology for hematopoietic stem cells and bone marrow hematopoiesis, applied in the field of hematopoietic stem cells, can solve problems such as inability to clinically treat, large side effects, and inability to radically cure, and achieves the effects of reducing treatment risks, easy operation, and short time-consuming.

Active Publication Date: 2021-04-27
广东赤萌医疗科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] 1) Conservative treatment (regular long-term blood transfusion, iron removal therapy and splenectomy, etc.) Disadvantages: large side effects, high cost, no cure
However, the patient's autologous hematopoietic stem cells are genetically defective and cannot be directly used for clinical treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of hematopoietic stem cell and its preparation method and application
  • A kind of hematopoietic stem cell and its preparation method and application
  • A kind of hematopoietic stem cell and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Use the CRISPR-Sp Cas9 gene editing system to knock out the ZBTB7A gene, and the specific implementation steps are as follows:

[0050] 1. gRNA preparation

[0051] (1) according to the sequence design of ZBTB7A gene the gRNA sequence of 20nt, the target sequence of described gRNA is as shown in a kind of SEQ IDNO:1-SEQ ID NO:38;

[0052] (2) Synthesize the sense strand and antisense strand of the target sequence respectively (add cacc at the 5'-end of the sense strand, if the first nucleotide at the 5'-end of the sense strand is not guanine G, then add cacc at the 5'-end of the sense strand Add caccG at the -end; add aaac at the 5'-end of the antisense strand, if the first nucleotide at the 5'-end of the sense strand is not guanine G, then add C at the 3'-end of the antisense strand);

[0053] (3) The sense strand and antisense strand synthesized above were mixed, treated at 90°C, cooled naturally to room temperature for annealing treatment, and double-stranded DNA fr...

Embodiment 2

[0095] Use the CRISPR-Sa Cas9 gene editing system to knock out the ZBTB7A gene, and the specific implementation steps are as follows:

[0096] 1. gRNA preparation

[0097] (1) according to the sequence design of ZBTB7A gene the gRNA sequence of 21nt, the target sequence of described gRNA is as shown in one of SEQ IDNO:44-SEQ ID NO:38;

[0098] (2) Synthesize the sense strand and antisense strand of the target sequence respectively (add cacc at the 5'-end of the sense strand, if the first nucleotide at the 5'-end of the sense strand is not guanine G, then add cacc at the 5'-end of the sense strand Add caccG at the -end; add aaac at the 5'-end of the antisense strand, if the first nucleotide at the 5'-end of the sense strand is not guanine G, then add C at the 3'-end of the antisense strand);

[0099] (3) The sense strand and antisense strand synthesized above were mixed, treated at 90°C, cooled naturally to room temperature for annealing treatment, and double-stranded DNA frag...

Embodiment 3

[0140] The CRISPR-Sp Cas9 and CRISPR-Sa Cas9 gene editing systems were used respectively, combined with double gRNA to knock out the ZBTB7A gene. The specific implementation steps are as follows:

[0141] 1. The pX458 vector prepared in 3(6) of Example 1, which is connected with SEQ ID NO:26 and SEQ ID NO:37, is co-transformed into HEK 293T cells according to the method of 4 in Example 1, and then carried out according to the steps of 5 T7E1 enzyme digestion analysis of cutting efficiency;

[0142] 2. The pX601 vector prepared in 3(6) of Example 2, which is connected with SEQ ID NO:48 and SEQ ID NO:63, is co-transformed into HEK 293T cells according to the method of 4 in Example 2, and then carried out according to the step 5 T7E1 enzyme digestion analysis of cutting efficiency;

[0143] 3. Use 2% agarose gel electrophoresis to detect the effect of the above enzyme digestion, the results are as follows Figure 5 Shown: Each lane is named after the type of CRISPR system (Sp C...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a hematopoietic stem cell, wherein the ZBTB7A gene expression of the hematopoietic stem cell is reduced or not expressed. The present invention uses CRISPR technology to knock out the fetal hemoglobin gene inhibitor, which is easy to operate and takes a short time; the fetal hemoglobin gene inhibitor-ZBTB7A has no effect on the normal function of nucleated red blood cells after knockout, and expands the thalassemia The treatment method; the patient's own hematopoietic stem cells are used as the transplant body, which completely avoids the immune rejection of the transplantation and reduces the risk of stem cell therapy.

Description

technical field [0001] The invention relates to a hematopoietic stem cell, in particular to a hematopoietic stem cell with no expression or decreased expression of ZBTB7A gene, its preparation method and application. Background technique [0002] The 2008 WHO Global Epidemiology Report on Hemoglobinopathies pointed out that about 71% of the population in 229 countries had hemoglobinopathies, a major health problem. Newborns born in these countries account for 89% of the world's newborns, of which more than 330,000 newborns per year are associated with hemoglobinopathy (83% of which are sickle cell disease and 17% are thalassemia). Hemoglobinopathies accounted for about 3.4% of deaths among children under 5 years of age. [0003] In my country, there are about 56,000 cases of β-thalassemia major each year, at least 30,000 of whom need standardized blood transfusions to survive, and about 5,500 cases of α-thalassemia major die of perinatal causes every year. Southern my coun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N5/10A61K35/28A61P7/06
CPCA61K35/28C07K14/47C12N5/0647C12N2510/00
Inventor 祝海宝刘方方唐忆琳罗思施黄雨亭陶米林梁福才
Owner 广东赤萌医疗科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com